Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink market. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group.

A new "International Consensus Document" is dealing with the various applications of "Topical Oxygene Therapies" in woundhealing. "Granulox" developed by Sangui and licenced to Mölnlycke, is given an extended review on pages 16,17 as stand-alone therapy, regarding the mode of application.

Mölnlycke releases Granulox® in the Middle East & Africa

Acquistion of SastoMed by Mölnlycke - future relation with Sangui

"Motivations and goals following the acquisition of SastoMed GmbH by the Mölnlycke Group"